Floatz logo

PEGFILGRASTIM

Chemotherapy-induced Neutropenia

BeyondSpring Pharmaceuticals Inc.protein_peptidePhase 3Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Chemotherapy-induced Neutropenia cohort.

Asset / SponsorPhaseRating
Inno-206
BeyondSpring Pharmaceuticals Inc.
Phase 3BB
EMPEGFILGRASTIM
Biocad
Phase 3BB
FILGRASTIM
Ankara Etlik City Hospital
Phase 3BB
Docetaxel
BeyondSpring Pharmaceuticals Inc.
Phase 3BB
Pegfilgrastim bmez
Sandoz
Phase 3BB

View all 25 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →